A randomized placebo-controlled trial of paroxetine for the management of anxiety in chronic obstructive pulmonary disease (PAC Study)
Received 20 February 2018
Accepted for publication 11 April 2018
Published 27 June 2018 Volume 2018:11 Pages 287—293
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Zafar A Usmani,1,2 Kristin V Carson-Chahhoud,1,3 Adrian J Esterman,4,5 Brian J Smith1,2
1School of Medicine, The University of Adelaide, Adelaide, SA, Australia; 2Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, SA, Australia; 3School of Health Sciences, The University of South Australia, Adelaide, SA, Australia; 4School of Nursing and Midwifery, The University of South Australia, Adelaide, SA, Australia; 5Australian Institute of Tropical Health Medicine, James Cook University, Cairns, QLD, Australia
Background: Despite the high prevalence of anxiety in COPD patients and its impact on quality of life, evidence to support the effectiveness of various anxiety treatment options is insufficient, leading to the need for further research in this field.
Aim: The aim of this study was to assess the efficacy and safety of paroxetine for the management of anxiety in COPD and the impact of treatment on patients’ quality of life and rate of hospitalization.
Patients and methods: In a double-blind, randomized, controlled trial, COPD patients were allocated into groups that either received paroxetine 20 mg or placebo pills daily, for four months. Differences in outcomes were assessed based on an intention-to-treat analysis using linear mixed effects models. A chi-square test was used to compare the number of COPD-related admissions.
Results: Thirty-eight participants were recruited. Twenty-two of these completed the trial. A clinically and statistically significant reduction was noted in anxiety symptoms after four months of treatment compared to the placebo. Clinically important improvement was noted in depression symptoms, with no statistically significant differences in walking distance or quality-of-life measure outcomes. The intervention group had less COPD-related admissions compared to the placebo group but experienced medication-related side effects.
Conclusion: Treatment with paroxetine significantly improved anxiety levels, but this difference did not translate into improved quality of life at four months follow-up.
Keywords: anxiety, COPD, pharmacotherapy, paroxetine, BAI, emphysema
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]